148 related articles for article (PubMed ID: 32770956)
1. The burden of hyperkalemia in Germany - a real world evidence study assessing the treatment and costs of hyperkalemia.
Haas JS; Krinke KS; Maas C; Hardt T; Barck I; Braun S
BMC Nephrol; 2020 Aug; 21(1):332. PubMed ID: 32770956
[TBL] [Abstract][Full Text] [Related]
2. The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings.
Neuenschwander JF; Silverstein AR; Teigland CL; Kumar S; Zeng EY; Agiro AT; Pottorf WJ; Peacock WF
Adv Ther; 2023 Mar; 40(3):1204-1223. PubMed ID: 36652174
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure.
Polson M; Lord TC; Kangethe A; Speicher L; Farnum C; Brenner M; Oestreicher N; Alvarez P
J Manag Care Spec Pharm; 2017 Apr; 23(4-a Suppl):S2-S9. PubMed ID: 28436256
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study.
Kim K; Thomsen RW; Nicolaisen SK; Hasvold LP; Palaka E; Sørensen HT
BMJ Open; 2019 Apr; 9(4):e026465. PubMed ID: 30940761
[TBL] [Abstract][Full Text] [Related]
5. Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy.
Provenzano M; De Francesco M; Iannazzo S; Garofalo C; Andreucci M; Genualdo R; Borrelli S; Minutolo R; Conte G; De Nicola L
Int J Clin Pract; 2020 May; 74(5):e13475. PubMed ID: 31909866
[TBL] [Abstract][Full Text] [Related]
6. [Effect of hyperkalemia and RAASi nonadherence on patients affected by heart failure or chronic kidney disease].
Degli Esposti L; Perrone V; Giacomini E; Sangiorgi D; Alessandrini D; Santoro A
G Ital Nefrol; 2019 Sep; 36(5):. PubMed ID: 31580544
[TBL] [Abstract][Full Text] [Related]
7. Association of hyperkalemia with clinical outcomes in advanced chronic kidney disease.
Caravaca-Fontán F; Valladares J; Díaz-Campillejo R; Barroso S; Luna E; Caravaca F
Nefrologia (Engl Ed); 2019; 39(5):513-522. PubMed ID: 31027897
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England.
Horne L; Ashfaq A; MacLachlan S; Sinsakul M; Qin L; LoCasale R; Wetmore JB
BMC Nephrol; 2019 Mar; 20(1):85. PubMed ID: 30841854
[TBL] [Abstract][Full Text] [Related]
9. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study.
Thomsen RW; Nicolaisen SK; Hasvold P; Sanchez RG; Pedersen L; Adelborg K; Egstrup K; Egfjord M; Sørensen HT
Nephrol Dial Transplant; 2018 Sep; 33(9):1610-1620. PubMed ID: 29177463
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and economic burden of hyperkalemia in the United States Medicare population.
Mu F; Betts KA; Woolley JM; Dua A; Wang Y; Zhong J; Wu EQ
Curr Med Res Opin; 2020 Aug; 36(8):1333-1341. PubMed ID: 32459116
[No Abstract] [Full Text] [Related]
11. Real-world management of hyperkalemia with patiromer among United States Veterans.
Kovesdy CP; Gosmanova EO; Woods SD; Fogli JJ; Rowan CG; Hansen JL; Sauer BC
Postgrad Med; 2020 Mar; 132(2):176-183. PubMed ID: 31971043
[No Abstract] [Full Text] [Related]
12. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology.
Bianchi S; Aucella F; De Nicola L; Genovesi S; Paoletti E; Regolisti G
J Nephrol; 2019 Aug; 32(4):499-516. PubMed ID: 31119681
[TBL] [Abstract][Full Text] [Related]
13. Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis.
Muhlestein JB; Kammerer J; Bair TL; Knowlton KU; Le VT; Anderson JL; Lappé DL; May HT
BMC Prim Care; 2022 Apr; 23(1):65. PubMed ID: 35365076
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Hyperkalemia on Mortality and Healthcare Resource Utilization Among Patients With Chronic Kidney Disease: A Matched Cohort Study in China.
Zhang J; He X; Wu J
Front Public Health; 2022; 10():855395. PubMed ID: 35400057
[TBL] [Abstract][Full Text] [Related]
15. Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey.
Rossignol P; Lamiral Z; Frimat L; Girerd N; Duarte K; Ferreira J; Chanliau J; Castin N
Nephrol Dial Transplant; 2017 Dec; 32(12):2112-2118. PubMed ID: 28460113
[TBL] [Abstract][Full Text] [Related]
16. Elevated Potassium Levels in Patients With Congestive Heart Failure: Occurrence, Risk Factors, and Clinical Outcomes: A Danish Population-Based Cohort Study.
Thomsen RW; Nicolaisen SK; Hasvold P; Garcia-Sanchez R; Pedersen L; Adelborg K; Egfjord M; Egstrup K; Sørensen HT
J Am Heart Assoc; 2018 May; 7(11):. PubMed ID: 29789332
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization and expenditures associated with hyperkalemia management: a retrospective study of Medicare Advantage patients.
Desai NR; Alvarez PJ; Golestaneh L; Woods SD; Coca SG; Rowan CG
J Med Econ; 2021; 24(1):1025-1036. PubMed ID: 34357841
[TBL] [Abstract][Full Text] [Related]
18. Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions.
Tafesse E; Hurst M; Hoskin L; Badora K; Sugrue D; Qin L; James G; McEwan P
Int J Clin Pract; 2021 Apr; 75(4):e13941. PubMed ID: 33332710
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of hyperkalemia in the United States.
Betts KA; Woolley JM; Mu F; McDonald E; Tang W; Wu EQ
Curr Med Res Opin; 2018 Jun; 34(6):971-978. PubMed ID: 29368958
[TBL] [Abstract][Full Text] [Related]
20. Healthcare costs in chronic kidney disease and renal replacement therapy: a population-based cohort study in Sweden.
Eriksson JK; Neovius M; Jacobson SH; Elinder CG; Hylander B
BMJ Open; 2016 Oct; 6(10):e012062. PubMed ID: 27855091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
